Clinical trials: Itching
Chronic Spontaneous Urticaria
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1-antihistamines
The purpose of this study was to establish the efficacy, safety, and tolerability of Remibrutinib 25 mg b.i.d. in adult patients suffering from chronic spontaneous urticaria (CSU) inadequately controlled by second generation…
- Trial name
- REMIX-2 (NCT05032157)
- Testing
- LOU064 (blinded), LOU064 (open-label)
- Where
- 122 sites in United States, Austria and 16 more
- Volunteers
- 455 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque-type Psoriasis
Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab
The aim of this study was to describe the effect of direct IL-17A inhibition with secukinumab as compared with the selective inhibition of IL-23 with guselkumab (p19 subunit blocker) in controlling inflammation in psoriatic…
- Trial name
- ARROW (NCT03553823)
- Testing
- Skin biopsies
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Atopic Dermatitis (AD)
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and tolerability of ruxolitinib cream in adolescents with Atopic Dermatitis (AD).
- Trial name
- NCT05456529
- Testing
- Ruxolitinib Cream
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 103 people
- Sponsor
- Incyte Corporation
Uremic Pruritus
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
This a multicentre study that consists of a 12-week double-blind period, and an optional 14-week open-label extension period and a 1-week follow-up period.
- Trial name
- NCT05885737
- Testing
- Difelikefalin Injection
- Where
- 35 sites in China
- Volunteers
- 260 people
- Sponsor
- Vifor Fresenius Medical Care Renal Pharma
Dermatitis, Atopic
A Study of an Eczema Spot Treatment in Providing Eczema Symptoms Relief and Lasting Itch Relief to Affected Skin Area
The purpose of this study is to evaluate the efficacy (assessed by clinical evaluation of eczema/atopic lesion severity [atopic dermatitis severity index {ADSI} scoring] and perceived benefits in itch [visual analog score {VAS}…
- Trial name
- NCT05226143
- Testing
- Gel Cream
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Tinea Pedis
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with…
- Trial name
- NCT01580878
- Testing
- Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle
- Volunteers
- 707 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Tinea Pedis
Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis
To assess the efficacy and safety of a combination product S2G6T-1 compared to its monads and vehicle, applied twice daily for 7 days, in the treatment of symptomatic inflammatory interdigital tinea pedis in subjects 12 years of…
- Trial name
- NCT02842021
- Testing
- S2G6T-1, S2G6T-2, S2G6T-3
- Where
- 19 sites in United States
- Volunteers
- 283 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Pruritus
A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects
The primary objective is to confirm the target receptor occupancy of SK-1405 and to correlate receptor occupancy with SK-1405 dose and plasma concentration.
- Trial name
- NCT02650076
- Testing
- SK-1405
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Bacterial Vaginoses
Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV
A multi-center, open-label study to evaluate the treatment of one oral dose of 2g Solosec™ (Secnidazole) in adolescent girls with BV
- Trial name
- NCT03937869
- Testing
- Secnidazole
- Where
- 9 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Lupin Research Inc
Chronic Pruritus of Unknown Origin
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).
- Trial name
- NCT07811869
- Testing
- Remibrutinib
- Where
- 7 sites in United States
- Volunteers
- 180 people
- Sponsor
- Novartis Pharmaceuticals
Eczema, Allergy Symptoms
Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream
This is a multi-center, open-label study to evaluate whether participants follow the duration of use instructions for short-term use of alclometasone dipropionate in a population of participants with itchy skin conditions who…
- Conditions
- Eczema, Allergy Symptoms, Psoriasis, Itch
- Trial name
- NCT02075632
- Testing
- Alclometasone dipropionate cream
- Volunteers
- 310 people
- Sponsor
- GlaxoSmithKline
Uremic Pruritus in Hemodialysis Patients
A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus
The purpose of this study is to evaluate the efficacy, safety and dose response of SK-1405 for the treatment of subjects with uremic pruritus receiving hemodialysis, during 2 weeks of treatment.
- Trial name
- NCT03218501
- Testing
- SK-1405 high dose, SK-1405 low dose
- Where
- Japan
- Volunteers
- 269 people
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
Skin Pruritus
A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus
The study is a Phase II, multi center, randomized, double-blind, placebo-controlled study in male and female subjects, aged ≥ 19 years with skin pruritus.
- Trial name
- NCT02565134
- Testing
- PAC-14028 cream 0.1%, PAC-14028 cream 0.3%, PAC-14028 cream 1.0%
- Where
- South Korea
- Volunteers
- 296 people
- Sponsor
- Amorepacific Corporation
Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension…
- Trial name
- NCT05061693
- Testing
- INCB054707
- Where
- 49 sites in United States, Canada and 4 more
- Volunteers
- 146 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)
The purpose and (primary) objectives of this study are to evaluate the efficacy, safety, and tolerability of TS-022 in adults with atopic dermatitis who have moderate to very severe pruritus (itching), following a 28-day regimen…
- Trial name
- NCT00914186
- Testing
- TS022, Vehicle
- Where
- 15 sites in United States
- Volunteers
- 122 people
- Sponsor
- Taisho Pharmaceutical R&D Inc.
Atopic Dermatitis
To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)
This is a Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmaceuticals, Ltd) to the Marketed Product…
- Trial name
- NCT02601703
- Testing
- Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%
- Where
- 60 sites in United States
- Volunteers
- 1,110 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Chronic Spontaneous Urticaria
A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.
The purpose of the study is to learn about the safety and effects of the study medicine (called ritlecitinib) for the treatment of chronic spontaneous urticaria (CSU) that is not effectively treated by antihistamines which are…
- Trial name
- NCT07219615
- Testing
- Ritlecitinib 50 mg, Ritlecitinib 100 mg
- Where
- 77 sites in United States, Bulgaria and 8 more
- Volunteers
- 200 people
- Sponsor
- Pfizer
Atopic Dermatitis
A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis
This was a randomized, double blind, placebo controlled, parallel group study in approximately 90 subjects with moderate-severe AD Eczema Area and Severity Index (EASI) ≥12 and ≤ 48 (0-72 scale).
- Trial name
- NCT02424253
- Testing
- ZPL-3893787
- Where
- 17 sites in Belgium, Germany and 2 more
- Volunteers
- 98 people
- Sponsor
- Ziarco Pharma Ltd
Itching
Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal
Open, single-arm, non-randomized study to demonstrate the efficacy of Remo-Wax® Oil (abbreviated RWO) in the treatment of isolated itching of the external ear canal and to demonstrate the safety of the product.
- Trial name
- Remo_Itch (NCT05811039)
- Testing
- Remo-Wax® Oil
- Where
- Lithuania
- Volunteers
- 36 people
- Sponsor
- Orion Corporation, Orion Pharma
Skin Pruritus, Itch
Efficacy and Safety of HA35 Gel for Ultra-Rapid Skin Pruritus Relief
This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel for ultra-rapid relief of moderate-to-severe skin pruritus…
- Conditions
- Skin Pruritus, Itch, Eczema Itch, Neurodermatitis
- Trial name
- HA35-ITCH (NCT07580911)
- Testing
- 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Anti-Pruritic Gel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nakhia Impex LLC